Home

Mission

The mission of the Center for Neurodegenerative Disease Research (CNDR) is to promote and conduct multidisciplinary clinical and basic research to increase the understanding of the causes and mechanisms leading to brain dysfunction and degeneration in neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Lewy body dementia (LBD), Frontotemporal degeneration (FTD), Amyotrophic lateral sclerosis (ALS), Primary lateral sclerosis (PLS), Motor neuron disease (MND), and related disorders that occur increasingly with advancing age. Implicit in the mission of the CNDR are two overarching goals: 1.) Find better ways to cure and treat these disorders, 2. Provide training to the next generation of scientists.

“My goal for CNDR is not only to collaborate with researchers at Penn and from institutions across the globe with the mutual goal of finding better ways to diagnose and treat neurodegenerative diseases, but also to inspire and encourage the next generation of scientists on the importance of investigating these disorders that occur more frequently with advancing age.” – Virginia M.-Y. Lee, PhD, Director, CNDR

collage

 

John Q. Trojanowski, MD, PhD | 1946 - 2022

johnFebruary 8, 2022

We are sad to announce the passing of our colleague and friend, John Q. Trojanowski, who we all regard as a larger than life leader in neurodegenerative disease research.   We will miss his probing intellect, limitless enthusiasm and energy, and ever present personality.  He passed away peacefully with Virginia, his partner in every aspect of his life, by his side.  I know the thoughts of our entire community go out to Virginia and her family.  While today is a difficult day for so many of us, we do look forward to finding ways to celebrate his remarkable life in the future. 

Contribute to the John Q. Trojanowski, M.D., Ph.D. Memorial Fund at the Center for Neurodegenerative Disease Research

Latest Research

  • Highly tunable bimane-based fluorescent probes: design, synthesis, and application as a selective amyloid binding dye Friday, April 26, 2024

    Small molecule fluorescent probes are indispensable tools for a broad range of biological applications. Despite many probes being available, there is still a need for probes where photophysical properties and biological selectivity can be tuned as desired. Here, we report the rational design and synthesis of a palette of fluorescent probes based on the underexplored bimane scaffold. The newly developed probes with varied electronic properties show tunable absorption and emission in the visible...

  • Insight in obsessive-compulsive disorder: conception, clinical characteristics, neuroimaging, and treatment Friday, April 26, 2024

    Obsessive-compulsive disorder (OCD) is a chronic disabling disease with often unsatisfactory therapeutic outcomes. The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) has broadened the diagnostic criteria for OCD, acknowledging that some OCD patients may lack insight into their symptoms. Previous studies have demonstrated that insight can impact therapeutic efficacy and prognosis, underscoring its importance in the treatment of mental disorders, including OCD....

  • In Their Own Words: Fears Expressed by People with Parkinson's Disease in an Online Symptom Database Friday, April 26, 2024

    Parkinson's disease (PD) carries substantial psychosocial burden. Using a database of responses by people with PD reporting up to five "most bothersome problems," we identified 225 fear-based verbatims, which were organized using the framework method into 26 categories. Commonly-reported fears included uncertainty of progression (n = 60, 26.7%), fear of future cognitive impairment (n = 24, 10.7%) and fear of becoming a burden on others (n = 23, 10.2%). Fears in PD are wide-ranging and can...

More News